PURPOSE: The aim of this study was to evaluate the efficacy and safety of redistributed subclavian arterial infusion chemotherapy (RESAIC). We have focused on the local response, quality of life (QOL), and complications. We have also investigated factors that influence the local response of RESAIC. MATERIALS AND METHODS: The subjects were patients with locally advanced breast cancer whose tumors were resistant to standard systemic chemotherapy (at least more than two regimens), those who were physically unable to tolerate systemic chemotherapy, and patients with locally recurrent breast cancer. The registration period was between April 2006 and May 2009. RESULTS: A total of 24 cases in 22 patients (mean age 59.5 years, range 36-82 years) were entered in the study. The local response rate of RESAIC was 77.3% (17/22). The QOL score showed improvement on average. There were no serious complications during catheter port implantation, and there was hematological toxicity over grade 3 in 27.3% (6/22) of patients. A significant difference between responders and nonresponders was seen in patients with a replaced type tumor (on imaging, diffuse contrast enhancement was seen in whole quadrants) (P = 0.043), and the patients underwent radiotherapy (P = 0.043). CONCLUSION: RESAIC is an effective, safe treatment for locally advanced breast cancer. Because it was reviewed in only a few cases, however, large-scale studies are warranted.
PURPOSE: The aim of this study was to evaluate the efficacy and safety of redistributed subclavian arterial infusion chemotherapy (RESAIC). We have focused on the local response, quality of life (QOL), and complications. We have also investigated factors that influence the local response of RESAIC. MATERIALS AND METHODS: The subjects were patients with locally advanced breast cancer whose tumors were resistant to standard systemic chemotherapy (at least more than two regimens), those who were physically unable to tolerate systemic chemotherapy, and patients with locally recurrent breast cancer. The registration period was between April 2006 and May 2009. RESULTS: A total of 24 cases in 22 patients (mean age 59.5 years, range 36-82 years) were entered in the study. The local response rate of RESAIC was 77.3% (17/22). The QOL score showed improvement on average. There were no serious complications during catheter port implantation, and there was hematological toxicity over grade 3 in 27.3% (6/22) of patients. A significant difference between responders and nonresponders was seen in patients with a replaced type tumor (on imaging, diffuse contrast enhancement was seen in whole quadrants) (P = 0.043), and the patients underwent radiotherapy (P = 0.043). CONCLUSION: RESAIC is an effective, safe treatment for locally advanced breast cancer. Because it was reviewed in only a few cases, however, large-scale studies are warranted.
Authors: M Murakami; Y Kuroda; S Nishimura; A Sano; Y Okamoto; T Taniguchi; T Nakajima; Y Kobashi; S Matsusue Journal: Am J Clin Oncol Date: 2001-04 Impact factor: 2.339
Authors: Paola Pacetti; Andrea Mambrini; Rocco Paolucci; Franco Sanguinetti; Beniamino Palmieri; Roberta Della Seta; Maria Pia Muttini; Giammaria Fiorentini; Maurizio Cantore Journal: In Vivo Date: 2006 Nov-Dec Impact factor: 2.155
Authors: W Heller; D Mazhar; R Ward; H D Sinnett; C Lowdell; R Phillips; S Shousha; A Fayaz; C Palmieri; R C Coombes Journal: Oncol Rep Date: 2007-01 Impact factor: 3.906
Authors: M J Brady; D F Cella; F Mo; A E Bonomi; D S Tulsky; S R Lloyd; S Deasy; M Cobleigh; G Shiomoto Journal: J Clin Oncol Date: 1997-03 Impact factor: 44.544
Authors: J E Olson; D Neuberg; K J Pandya; M P Richter; L J Solin; K W Gilchrist; D C Tormey; M Veeder; G Falkson Journal: Cancer Date: 1997-03-15 Impact factor: 6.860